Study explores Cytosorb clearance of cell-free hemoglobin
Bottom line
Hemoadsorption with the CytoSorb adsorber reduced cell-free hemoglobin in an in vitro porcine blood model, according to a new study in the American Journal of Veterinary Research. The study tested the cartridge’s clearance capacity in 1,000 mL aliquots of hemolyzed porcine blood and adds to a small but growing veterinary evidence base around extracorporeal adsorption technologies. While this was a laboratory study rather than a clinical trial, it suggests the device may have potential relevance in settings where free hemoglobin contributes to oxidative stress, vascular dysfunction, and downstream organ injury. Related veterinary literature remains limited, but recent work has explored the same platform for cytokine removal, bilirubin reduction, and hemoperfusion in toxicities and immune-mediated hemolytic disease. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the finding is less about immediate practice change and more about mechanism and feasibility. Cell-free hemoglobin is a biologically active breakdown product associated with endothelial injury and inflammatory effects, and adsorption-based extracorporeal support could eventually become a niche adjunct in severe hemolysis or other critical care scenarios. But the field is still early: current veterinary guidance describes hemoperfusion as an evolving modality, and the strongest published veterinary support so far is in consensus guidance and small case series, not outcome-driven trials for hemoglobin clearance in clinical patients. (pmc.ncbi.nlm.nih.gov)
What to watch: The next step is whether these in vitro findings are followed by controlled in vivo studies, then real-world clinical reports that show not just removal of cell-free hemoglobin, but meaningful patient benefit. (pmc.ncbi.nlm.nih.gov)
Key facts
- Study type
- In vitro laboratory study
- Species
- Porcine blood
- Device
- CytoSorb adsorber
- Journal
- American Journal of Veterinary Research
- Objective
- Measure maximum clearance capacity for cell-free hemoglobin
- Finding
- Reduced cell-free hemoglobin in hemolyzed porcine blood
- Clinical context
- Relevant to severe hemolysis and extracorporeal support
- Limitation
- Not a clinical trial
A new American Journal of Veterinary Research study reports that hemoadsorption with the CytoSorb adsorber can effectively reduce cell-free hemoglobin from porcine blood in vitro, adding another data point to the emerging veterinary literature on extracorporeal blood purification. The work focused on the cartridge’s maximum clearance capacity in a controlled laboratory model, not in live animals, but it addresses a clinically relevant target: circulating free hemoglobin, which has been linked to oxidative injury, nitric oxide scavenging, endothelial dysfunction, and organ damage. (pmc.ncbi.nlm.nih.gov)
That matters because hemoadsorption is gaining visibility in veterinary critical care, even as evidence remains limited and highly indication-specific. An International Renal Interest Society consensus document published in the past year described hemoperfusion for veterinary toxicities as a rapidly evolving area and emphasized that recommendations will likely change as devices and data mature. Separately, AJVR published ex vivo work in horses showing that a related veterinary-branded adsorber could remove inflammatory mediators, underscoring broader interest in adsorption platforms beyond toxin management alone. (pubmed.ncbi.nlm.nih.gov)
The new porcine study also fits into a research line coming out of the same academic environment. A recent open-access pilot study by overlapping investigators evaluated the CytoSorb adsorber in canine hemolyzed blood in vitro and reported that the device reduced cell-free hemoglobin concentrations over time while adsorption was strongest early in treatment and tapered as the cartridge approached saturation. That canine paper described the device as a whole-blood adsorber using porous polystyrene-divinylbenzene beads with a stated binding range of roughly 5 to 60 kDa, a range that includes substances such as bilirubin, myoglobin, some inflammatory mediators, and cell-free hemoglobin. (pmc.ncbi.nlm.nih.gov)
Beyond hemoglobin, the same platform has already appeared in other veterinary reports. A three-dog case series described use of the veterinary-specific VetResQ adsorber alongside therapeutic plasma exchange in immune-mediated hemolytic anemia, and a more recent canine case report described improved bilirubin reduction when hemoperfusion was added to plasma exchange. Experimental and case-based literature has also examined hemoperfusion in horses and in toxicology settings, suggesting that clinicians are exploring these cartridges across several severe-care scenarios rather than for one narrow indication. (pmc.ncbi.nlm.nih.gov)
Expert reaction specific to this porcine paper was limited in publicly accessible sources, but the broader tone in the field is cautious rather than promotional. The IRIS consensus guidance frames hemoperfusion as promising, but still dependent on expert opinion and evolving manufacturer information. That caution is consistent with the human literature as well: studies have shown the device can remove free hemoglobin and other target molecules, yet clinical benefit has been inconsistent across indications, and adsorption of concurrently administered drugs remains an important practical concern. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is an early-stage translational signal, not a practice-changing result. The study strengthens the biologic plausibility that adsorption therapy could help manage consequences of marked hemolysis, particularly in referral or academic settings already using extracorporeal support. But in vitro clearance does not automatically translate into better survival, shorter hospitalization, or reduced organ injury in dogs, cats, or horses. Questions around timing, cartridge saturation, anticoagulation, patient selection, cost, staffing, and unintended removal of medications will all matter if this approach moves closer to clinical use. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for full publication details from AJVR, any follow-on in vivo animal studies, and whether investigators can connect adsorption of cell-free hemoglobin to clinical endpoints in hemolytic disease, critical care, or extracorporeal support cases. If those studies emerge, they’ll likely determine whether hemoadsorption remains a niche academic tool or becomes a more practical option for specialty hospitals treating severe hemolysis and related complications. (pmc.ncbi.nlm.nih.gov)